NASDAQ:FATE

Fate Therapeutics Earning Date

USA |NASDAQ |USD

FATE Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 3, 2021 Sep 2021 $-0.58 $-0.58 $-0.68
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 3, 2021 Sep 2021 $7.89M $13.41M $7.56M

Fate Therapeutics's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.

FATE Earnings Date & History Chart

FATE Earnings & Revenue Forecast

FATE Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 16 $-0.58 $-0.66 $-0.40
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 18 $-2.24 $-2.37 $-1.87
Dec 2022 18 $-2.64 $-3.21 $-1.78

FATE Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.58 $-0.57 $-0.56
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-2.25 $-2.25 $-2.13
Dec 2022 0 / 0 $-2.65 $-2.54 $-2.51

FATE Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 16 $9.22M $0.00 $15.00M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 19 $42.79M $25.00M $58.35M
Dec 2022 19 $37.94M $0.00 $87.00M

FATE Earnings Date & Revenue History

FATE Earnings History

|
Show More
Show More

FATE Revenue History

|
Show More
Show More

Fate Therapeutics Next Earnings Date & Report

FATE Next Earnings Date & Report Preview: Sep 2021 (FQ)

FATE's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 16 analysts, the average EPS estimation for Fate Therapeutics's next quarterly earnings is $-0.58, with a low EPS estimation of $-0.74, and a high estimation of $-0.41.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.58, the last 2 month trend is $-0.57, and the 3 month trend is $-0.55.

Based on 16 analysts, the average revenue estimation is $7.89M, with a low revenue estimation of $0.00, and a high estimation of $15.00M.

Fate Therapeutics Previous Earnings Dates & Reports

FATE Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Fate Therapeutics's previous earnings date was Aug 4, 2021 for its fiscal quarter ended Jun 30, 2021.

FATE's earnings per share (EPS) was $-0.58, missing the consensus analysts forecast of $-0.52 by -11.62%.

The EPS was lower than the previous fiscal quarter (Mar 2021) by 31.82%, and lower than the same period a year before (Jun 2020) by 65.71%.

Revenues were $13.41M, better than the forecast of $13.41M by 0.00%, up by 20.37% from the previous quarter , and up by 145.42% from the same period last year.

The company reported a net income of $-55.13M.

Free cash flow for the quarter was $-45.73M , compared to $-31.08M last quarter and $38.20M a year before.

FATE ended the quarter with $110.47M in total debt, a decrease of -0.41% compared to the previous quarter, and an increase of 36.32% compared to the same quarter a year before.

FATE Previous Earnings Date & Report Recap: Dec 2020 (FY)

Fate Therapeutics's previous annual earnings date was Feb 24, 2021 for its fiscal year ended Dec 31, 2020.

FATE's earnings per share (EPS) was $-2.08, missing the consensus analysts forecast of $-1.83 by 13.66% , and lower than the previous year's EPS (Dec 2019) by 45.45%.

Revenues were $31.43M, better than the forecast of $20.42M by 53.94%, and up by 194.33% from previous year's revenue.

The company reported a net income of $-173.39M.

Fate Therapeutics reported a free cash flow of $-44.16M for its fiscal year, compared to $-90.57M a year ago.

The company ended the fiscal year with $97.30M in total debt, an increase of 261.34% compared to the previous year.